Journey Medical (NASDAQ:DERM – Get Free Report) and Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.
Risk & Volatility
Journey Medical has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.
Valuation & Earnings
This table compares Journey Medical and Syndax Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Journey Medical | $79.18 million | 1.43 | -$3.85 million | ($0.31) | -17.65 |
| Syndax Pharmaceuticals | $3.50 million | 440.96 | -$209.36 million | ($3.22) | -5.64 |
Profitability
This table compares Journey Medical and Syndax Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Journey Medical | 1.09% | 5.44% | 1.23% |
| Syndax Pharmaceuticals | N/A | -57.42% | -51.98% |
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Journey Medical and Syndax Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Journey Medical | 0 | 0 | 4 | 1 | 3.20 |
| Syndax Pharmaceuticals | 0 | 1 | 9 | 0 | 2.90 |
Journey Medical presently has a consensus price target of $9.38, suggesting a potential upside of 71.39%. Syndax Pharmaceuticals has a consensus price target of $35.33, suggesting a potential upside of 94.57%. Given Syndax Pharmaceuticals’ higher probable upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Journey Medical.
Insider & Institutional Ownership
7.3% of Journey Medical shares are held by institutional investors. 19.4% of Journey Medical shares are held by company insiders. Comparatively, 4.1% of Syndax Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Journey Medical beats Syndax Pharmaceuticals on 10 of the 15 factors compared between the two stocks.
About Journey Medical
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Journey Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Journey Medical and related companies with MarketBeat.com's FREE daily email newsletter.
